Trial
NCT05472623
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Mirati Therapeutics Inc.; Bristol-Myers Squibb
Condition
Resectable Non-Small Cell Lung Cancer
Intervention
Adagrasib
Why stopped
no participants enrolled across sites
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-15